Abstract
Purpose :
To determine functional outcomes such as visual acuity, refractive errors and the occurrence of strabismus after intravitreal bevacizumab or laser photocoagulation or combination of both treatment for type 1 retinopathy of prematurity
Methods :
The data from infants treated with either IVB or PRP for type 1 ROP between 2008 and 2012 were recorded from Chang Gung Memorial Hospital in Linkou, Taiwan.
Results :
A total of 229 eyes (122 patients) with type 1 ROP were evaluated: 151 eyes (80 patients) received IVB, 41 eyes (23 patients) received PRP, and 37 eyes (19 patients) received combination of both treatments. Among the 151 eyes treated with IVB, 13 eyes had zone I ROP and 137 eyes had posterior zone II ROP. The number of zone I and II ROP eyes treated with PRP were 4 and 29, respectively. Mean gestational age, birth weight, postmenstrual age at initial treatment, and follow-up period for the infants receiving IVB were 26.8 weeks, 913.8 g, 37.4 weeks, and 40.6 weeks, respectively, and for the infants receiving PRP, these were 26.5 weeks, 887.1 g, 37.6 weeks, and 79.9 weeks, respectively, and for the infants receiving combination treatment, these were 25.1 weeks, 717.5 g, 34.3 weeks, and 63.2 weeks, respectively.
Conclusions :
At 49-60m, IVB group has the best logBCVA (0.15±0.25), followed by combination group (0.24±0.20) and LIO group (0.22±0.14). At the age of between 61 and 72 months, IVB has spherical equivalent (SE) of (0.48±2.86) diopter, followed by combination group (-0.78±2.03) diopter and LIO group (-2.03±4.30) diopter. At the age of less than 48 months, IVB has the highest percentage of ortho position (95.61%), followed by combination group (90.00%) diopter and LIO group (75.00%)
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.